60 minutes is considered “the most successful news magazine in TV history”. Don’t miss this CRISPR episode, featuring Feng Zhang, Eric Lander, Kang Zhang and Shoukhrat Mitalipov.
It was August 2 when Nature published the latest stunning study, introducing to the world the first human embryos edited in the US by Shoukhrat Mitalipov. Not even a month had passed, and on August 28, those results have been challenged on a much younger and quick medium: the bioRxiv pre-print website. I felt like a déjà vu happening. It reminded me of the Nature Methods study questioning CRISPR’s precision in June. Within three weeks bioRxiv has already challenged the controversial data about off-target mutations by posting two critical analyses which soon became three. In short, this server is rewriting a part of CRISPR’s science and it is becoming an emergency tool for correcting mistakes that, inevitably, sometimes tarnish the most respected peer-reviewed publications. How does it work? Continue reading
The exploit announced last week by Nature marks an advancement in CRISPR performance in human embryos big enough to say that yes, germ line editing will probably become a viable option sooner or later. It means that some genetic diseases (at least those caused by a single mutation) can be corrected not only in the treated individuals but also in their offspring. The idea of genetic diseases disappearing from the face of Earth is bound to remain a dream, as Eric Lander explained at the 2015 Washington Summit on Human Gene Editing. In short, with rare Mendelian diseases, the vast majority of situations can currently be addressed by in vitro fertilization and preimplantation genetic diagnosis, while complex diseases are, well, too complex to handle. Anyway, when you come to efficiency and accuracy, results achieved by Shoukhrat Mitalipov and colleagues are exciting: CRISPR science walks on robust and fast legs. As for the bioethics of the experiment, we should try not to get stuck with overused labels. Continue reading